The Automated Screening Working Groups is a group of software engineers and biologists passionate about improving scientific manuscripts on a large scale. Our members have created tools that check for common problems in scientific manuscripts, including information needed to improve transparency and reproducibility. We have combined our tools into a single pipeline, called ScreenIT. We're currently using our tools to screen COVID preprints.

About Followers

Latest preprint reviews

  1. A virus‐derived microRNA targets immune response genes during SARS‐CoV‐2 infection

    1. Meetali Singh
    2. Maxime Chazal
    3. Piergiuseppe Quarato
    4. Loan Bourdon
    5. Christophe Malabat
    6. Thomas Vallet
    7. Marco Vignuzzi
    8. Sylvie van der Werf
    9. Sylvie Behillil
    10. Flora Donati
    11. Nathalie Sauvonnet
    12. Giulia Nigro
    13. Maryline Bourgine
    14. Nolwenn Jouvenet
    15. Germano Cecere

    Reviewed by PREreview, ScreenIT

    2 evaluationsAppears in 2 listsLatest version Latest activity

  2. Dynamics, outcomes and prerequisites of the first SARS-CoV-2 superspreading event in Germany in February 2020: a cross-sectional epidemiological study

    1. Lukas Wessendorf
    2. Enrico Richter
    3. Bianca Schulte
    4. Ricarda Maria Schmithausen
    5. Martin Exner
    6. Nils Lehmann
    7. Martin Coenen
    8. Christine Fuhrmann
    9. Angelika Kellings
    10. Anika Hüsing
    11. Karl-Heinz Jöckel
    12. Hendrik Streeck

    Reviewed by ScreenIT

    1 evaluationAppears in 1 listLatest version Latest activity

  3. Entrectinib—A SARS-CoV-2 Inhibitor in Human Lung Tissue (HLT) Cells

    1. Alejandro Peralta-Garcia
    2. Mariona Torrens-Fontanals
    3. Tomasz Maciej Stepniewski
    4. Judith Grau-Expósito
    5. David Perea
    6. Vikram Ayinampudi
    7. Maria Waldhoer
    8. Mirjam Zimmermann
    9. María J. Buzón
    10. Meritxell Genescà
    11. Jana Selent

    Reviewed by ScreenIT

    1 evaluationAppears in 1 listLatest version Latest activity

  4. SARS-CoV-2 originated from SARS-CoV-1-related Bat-CoVs through Pan-CoVs rather than from SARS-CoV-2-related Bat-CoVs

    1. Perumal Arumugam Desingu
    2. K. Nagarajan

    Reviewed by ScreenIT

    1 evaluationAppears in 1 listLatest version Latest activity

  5. Neutralization of the SARS-CoV-2 Mu Variant by Convalescent and Vaccine Serum

    1. Keiya Uriu
    2. Izumi Kimura
    3. Kotaro Shirakawa
    4. Akifumi Takaori-Kondo
    5. Taka-aki Nakada
    6. Atsushi Kaneda
    7. So Nakagawa
    8. Kei Sato

    Reviewed by ScreenIT

    1 evaluationAppears in 1 listLatest version Latest activity

  6. Development and Validation of an Enzyme Immunoassay for Detection and Quantification of SARS-CoV-2 Salivary IgA and IgG

    1. Veronica P Costantini
    2. Kenny Nguyen
    3. Zoe Lyski
    4. Shannon Novosad
    5. Ana C Bardossy
    6. Amanda K Lyons
    7. Paige Gable
    8. Preeta K Kutty
    9. Joseph D Lutgring
    10. Amanda Brunton
    11. Natalie J Thornburg
    12. Allison C Brown
    13. L Clifford McDonald
    14. William Messer
    15. Jan Vinjé

    Reviewed by ScreenIT

    1 evaluationAppears in 1 listLatest version Latest activity

  7. Surveillance, contact tracing and characteristics of SARS-CoV-2 transmission in educational settings in Northern Italy, September 2020 to April 2021

    1. Olivera Djuric
    2. Elisabetta Larosa
    3. Mariateresa Cassinadri
    4. Silvia Cilloni
    5. Eufemia Bisaccia
    6. Davide Pepe
    7. Massimo Vicentini
    8. Francesco Venturelli
    9. Laura Bonvicini
    10. Paolo Giorgi Rossi
    11. Patrizio Pezzotti
    12. Alberto Mateo Urdiales
    13. Emanuela Bedeschi
    14. The Reggio Emilia Covid-19 Working Group

    Reviewed by ScreenIT

    1 evaluationAppears in 1 listLatest version Latest activity

  8. The early impact of vaccination against SARS-CoV-2 in Region Stockholm, Sweden

    1. Catherine Isitt
    2. Daniel Sjöholm
    3. Maria-Pia Hergens
    4. Fredrik Granath
    5. Pontus Nauclér

    Reviewed by ScreenIT

    1 evaluationAppears in 1 listLatest version Latest activity

  9. Potentially effective drugs for the treatment of COVID-19 or MIS-C in children: a systematic review

    1. Zijun Wang
    2. Siya Zhao
    3. Yuyi Tang
    4. Zhili Wang
    5. Qianling Shi
    6. Xiangyang Dang
    7. Lidan Gan
    8. Shuai Peng
    9. Weiguo Li
    10. Qi Zhou
    11. Qinyuan Li
    12. Joy James Mafiana
    13. Rafael González Cortés
    14. Zhengxiu Luo
    15. Enmei Liu
    16. Yaolong Chen

    Reviewed by ScreenIT

    1 evaluationAppears in 1 listLatest version Latest activity

  10. SARS-CoV-2 infection results in immune responses in the respiratory tract and peripheral blood that suggest mechanisms of disease severity

    1. Wuji Zhang
    2. Brendon Y. Chua
    3. Kevin J. Selva
    4. Lukasz Kedzierski
    5. Thomas M. Ashhurst
    6. Ebene R. Haycroft
    7. Suzanne K. Shoffner-Beck
    8. Luca Hensen
    9. David F. Boyd
    10. Fiona James
    11. Effie Mouhtouris
    12. Jason C. Kwong
    13. Kyra Y. L. Chua
    14. George Drewett
    15. Ana Copaescu
    16. Julie E. Dobson
    17. Louise C. Rowntree
    18. Jennifer R. Habel
    19. Lilith F. Allen
    20. Hui-Fern Koay
    21. Jessica A. Neil
    22. Matthew J. Gartner
    23. Christina Y. Lee
    24. Patiyan Andersson
    25. Sadid F. Khan
    26. Luke Blakeway
    27. Jessica Wisniewski
    28. James H. McMahon
    29. Erica E. Vine
    30. Anthony L. Cunningham
    31. Jennifer Audsley
    32. Irani Thevarajan
    33. Torsten Seemann
    34. Norelle L. Sherry
    35. Fatima Amanat
    36. Florian Krammer
    37. Sarah L. Londrigan
    38. Linda M. Wakim
    39. Nicholas J. C. King
    40. Dale I. Godfrey
    41. Laura K. Mackay
    42. Paul G. Thomas
    43. Suellen Nicholson
    44. Kelly B. Arnold
    45. Amy W. Chung
    46. Natasha E. Holmes
    47. Olivia C. Smibert
    48. Jason A. Trubiano
    49. Claire L. Gordon
    50. Thi H. O. Nguyen
    51. Katherine Kedzierska

    Reviewed by ScreenIT

    1 evaluationAppears in 1 listLatest version Latest activity
Newer Page 957 of 2361 Older